| MYRIAD GENETICS DL-,01 |
| USA |
| Gesundheit |
| US62855J1043 / 897518 |
| MYD (Frankfurt) / MYGN (NASDAQ) |
| FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN |
| - |
| https://myriad.com/ |
|
Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions. The company’s current portfolio spans oncology, women’s health, and..
>Volltext.. |
| 262.51 Mio. EUR |
| 346 Mio. EUR |
| 696.15 Mio. EUR |
| -35.73 Mio. EUR |
| -97.18 Mio. EUR |
| -1.03 EUR |
| 181.67 Mio. EUR |
| 99.42 Mio. EUR |
| 6.65 Mio. EUR |
| 0.88 |
| -0.11% |
| 70.61% |
| - |
| - |
| - |
| - |
| MYRIAD GENETICS |
| 07.09.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|